258 related articles for article (PubMed ID: 24475900)
1. Tumor infiltrating B-cells are increased in prostate cancer tissue.
Woo JR; Liss MA; Muldong MT; Palazzi K; Strasner A; Ammirante M; Varki N; Shabaik A; Howell S; Kane CJ; Karin M; Jamieson CA
J Transl Med; 2014 Jan; 12():30. PubMed ID: 24475900
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
Ryan ST; Zhang J; Burner DN; Liss M; Pittman E; Muldong M; Shabaik A; Woo J; Basler N; Cunha J; Shalapour S; Estrada MV; Karin M; Messer K; Howell S; Kane CJ; Jamieson CAM
J Transl Med; 2020 May; 18(1):214. PubMed ID: 32466781
[TBL] [Abstract][Full Text] [Related]
3. High intratumoral CD8
Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer.
Flammiger A; Bayer F; Cirugeda-Kühnert A; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
APMIS; 2012 Nov; 120(11):901-8. PubMed ID: 23009114
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Kärjä V; Aaltomaa S; Lipponen P; Isotalo T; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4435-8. PubMed ID: 16334122
[TBL] [Abstract][Full Text] [Related]
6. Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer.
Eriksen AC; Andersen JB; Kristensson M; dePont Christensen R; Hansen TF; Kjær-Frifeldt S; Sørensen FB
Diagn Pathol; 2017 Aug; 12(1):65. PubMed ID: 28851404
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
[TBL] [Abstract][Full Text] [Related]
8. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
9. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of B-cell density in cutaneous melanoma.
Ladányi A; Kiss J; Mohos A; Somlai B; Liszkay G; Gilde K; Fejös Z; Gaudi I; Dobos J; Tímár J
Cancer Immunol Immunother; 2011 Dec; 60(12):1729-38. PubMed ID: 21779876
[TBL] [Abstract][Full Text] [Related]
11. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D;
J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
[TBL] [Abstract][Full Text] [Related]
14. Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy.
Kobayashi T; Kimura T; Lee C; Inoue T; Terada N; Kono Y; Kamba T; Kim CS; Egawa S; Ogawa O
Jpn J Clin Oncol; 2016 Aug; 46(8):762-7. PubMed ID: 27207889
[TBL] [Abstract][Full Text] [Related]
15. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Bates AS; Mouraviev V; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Jun; 11(2):129-138. PubMed ID: 27435701
[TBL] [Abstract][Full Text] [Related]
16. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
Gielchinsky I; Chang J; Cusick T; Delprado W; Nguyen Q; Yuen C; Savdie R; Böhm M; Haynes AM; Scheltema MJ; Stricker PD
BJU Int; 2018 Nov; 122 Suppl 5():35-41. PubMed ID: 30303599
[TBL] [Abstract][Full Text] [Related]
18. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer.
Ayala G; Wang D; Wulf G; Frolov A; Li R; Sowadski J; Wheeler TM; Lu KP; Bao L
Cancer Res; 2003 Oct; 63(19):6244-51. PubMed ID: 14559810
[TBL] [Abstract][Full Text] [Related]
19. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
20. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]